Hoth Therapeutics Inc
HOTH
View Detailed Chart
1.090USD
+0.020+1.87%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
16.49MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.87%
5 Days
-6.84%
1 Month
+5.83%
6 Months
-9.92%
Year to Date
+45.70%
1 Year
+34.57%
View Detailed Chart
TradingKey Stock Score of Hoth Therapeutics Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Hoth Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.500
Target Price
+287.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Hoth Therapeutics Inc Highlights
StrengthsRisks
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Undervalued
The company’s latest PE is -1.29, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 264.95K shares, decreasing 49.46% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 38.80K shares of this stock.
Hoth Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Hoth Therapeutics Inc Info
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Ticker SymbolHOTH
CompanyHoth Therapeutics Inc
CEOKnie (Robb)
Websitehttps://hoththerapeutics.com/
FAQs
What is the current price of Hoth Therapeutics Inc (HOTH)?
The current price of Hoth Therapeutics Inc (HOTH) is 1.090.
What is the symbol of Hoth Therapeutics Inc?
The ticker symbol of Hoth Therapeutics Inc is HOTH.
What is the 52-week high of Hoth Therapeutics Inc?
The 52-week high of Hoth Therapeutics Inc is 3.800.
What is the 52-week low of Hoth Therapeutics Inc?
The 52-week low of Hoth Therapeutics Inc is 0.655.
What is the market capitalization of Hoth Therapeutics Inc?
The market capitalization of Hoth Therapeutics Inc is 16.49M.
What is the net income of Hoth Therapeutics Inc?
The net income of Hoth Therapeutics Inc is -8.19M.
Is Hoth Therapeutics Inc (HOTH) currently rated as Buy, Hold, or Sell?
According to analysts, Hoth Therapeutics Inc (HOTH) has an overall rating of Buy, with a price target of 4.500.
What is the Earnings Per Share (EPS TTM) of Hoth Therapeutics Inc (HOTH)?
The Earnings Per Share (EPS TTM) of Hoth Therapeutics Inc (HOTH) is -1.022.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
